JP2008538583A5 - - Google Patents

Download PDF

Info

Publication number
JP2008538583A5
JP2008538583A5 JP2008507988A JP2008507988A JP2008538583A5 JP 2008538583 A5 JP2008538583 A5 JP 2008538583A5 JP 2008507988 A JP2008507988 A JP 2008507988A JP 2008507988 A JP2008507988 A JP 2008507988A JP 2008538583 A5 JP2008538583 A5 JP 2008538583A5
Authority
JP
Japan
Prior art keywords
composition
subject
hydrogen
apathy
nefiracetam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008507988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538583A (ja
Filing date
Publication date
Priority claimed from US11/406,158 external-priority patent/US20060241144A1/en
Application filed filed Critical
Publication of JP2008538583A publication Critical patent/JP2008538583A/ja
Publication of JP2008538583A5 publication Critical patent/JP2008538583A5/ja
Withdrawn legal-status Critical Current

Links

JP2008507988A 2005-04-20 2006-04-19 アパシー症候群を治療するための方法 Withdrawn JP2008538583A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67355505P 2005-04-20 2005-04-20
US11/406,158 US20060241144A1 (en) 2005-04-20 2006-04-17 Method for treating apathy syndrome
PCT/US2006/015513 WO2006113937A2 (en) 2005-04-20 2006-04-19 Method for treating apathy syndrome

Publications (2)

Publication Number Publication Date
JP2008538583A JP2008538583A (ja) 2008-10-30
JP2008538583A5 true JP2008538583A5 (enExample) 2009-06-04

Family

ID=37115988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008507988A Withdrawn JP2008538583A (ja) 2005-04-20 2006-04-19 アパシー症候群を治療するための方法

Country Status (4)

Country Link
US (2) US20060241144A1 (enExample)
EP (1) EP1874300B1 (enExample)
JP (1) JP2008538583A (enExample)
WO (1) WO2006113937A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329741B2 (en) 2007-06-22 2012-12-11 The Research Foundation Of State University Of New York Substituted pyrrolidine compounds with central nervous system activity
ES2664727T3 (es) 2009-10-22 2018-04-23 University College Dublin National University Of Ireland, Dublin Terapia causal de enfermedades o estados asociados con desmielinización del SNC o del SNP
EP2672822A4 (en) * 2011-02-09 2014-08-27 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTIONS
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103044307A (zh) * 2013-01-24 2013-04-17 吉林三善恩科技开发有限公司 以2,4-二羟基苯甲酸为前驱体的吡拉西坦药物共晶及其制备方法
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
CN106511307B (zh) * 2015-09-11 2018-10-23 重庆润泽医药有限公司 一种（s）-4-羟基-2氧代-1-吡咯烷乙酰胺缓释胶囊及其制备方法
CN106619530A (zh) * 2015-10-27 2017-05-10 重庆润泽医药有限公司 一种左旋奥拉西坦颗粒及其制备方法
CN106890154B (zh) * 2015-12-17 2018-10-23 重庆润泽医药有限公司 一种左旋奥拉西坦泡腾片及其制备方法
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK279285B6 (sk) * 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
US5461157A (en) * 1992-06-19 1995-10-24 Daiichi Pharmaceutical Co., Ltd. Process for preparing pyrrolidinylacetamide derivatives
EP0819676B1 (en) * 1995-03-23 2002-09-25 Daiichi Pharmaceutical Co., Ltd. Anhydrous crystals
KR100417746B1 (ko) * 1995-07-21 2004-05-31 다이이찌 세이야꾸 가부시기가이샤 입상제제의제조방법
US6107330A (en) * 1995-08-07 2000-08-22 Daiichi Pharmaceutical Co., Ltd. Inhibitor for narcotic analgesic dependence/resistance acquisition
JPH0987178A (ja) 1995-09-22 1997-03-31 Toyama Chem Co Ltd 神経成長因子の作用増強剤
KR20000048847A (ko) * 1996-10-01 2000-07-25 스즈키 다다시 미토콘드리아 막 안정화제
AU8131198A (en) * 1997-07-15 1999-02-10 Daiichi Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for amnesia
TW544311B (en) * 1998-08-06 2003-08-01 Daiichi Seiyaku Co Therapeutic or preventive agent for intractable epilepsies
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
US6423739B1 (en) * 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration
US6348489B1 (en) * 2000-04-11 2002-02-19 Daiichi Pharmaceutical Co., Ltd. Method of treating traumatic brain injury and other neuronal disorders
KR100823668B1 (ko) * 2000-12-28 2008-04-21 해밀턴 파마슈티컬스 인코포레이티드 신경성 통증 치료 및 예방약
ATE404192T1 (de) * 2001-08-22 2008-08-15 Hamilton Pharmaceuticals Inc Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration

Similar Documents

Publication Publication Date Title
JP6595565B2 (ja) 免疫関連及び炎症性疾患の治療
CN1084618C (zh) 5－羟色胺拮抗剂的新应用
RU2317294C2 (ru) (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора
JP2007520520A5 (enExample)
JP5925065B2 (ja) 医薬組成物
JP2008195730A5 (enExample)
JP2007145875A5 (enExample)
HUP0204526A2 (hu) 2-Oxo-1-pirrolidin-származékok, eljárás előállításukra és alkalmazásuk
JP2006517939A5 (enExample)
JP2010534647A5 (enExample)
JP2006525276A5 (enExample)
JP2008513496A5 (enExample)
EA200801165A1 (ru) Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона
JP2020507602A5 (enExample)
RU2007120454A (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
US20250228838A1 (en) Methods of use of cyclic amide derivatives to treat sigma receptor mediated disorders
US20100099714A1 (en) AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
JP2012515763A5 (enExample)
MA28111A1 (fr) Derives des
RU2007119390A (ru) Соединения 4-метоксиметил-пирролидин-2-карбоновой кислоты и их производные - ингибиторы вируса гепатита с
JP2016537432A5 (enExample)
JP2004523557A5 (enExample)
JP2022527618A5 (enExample)
RU2311408C2 (ru) Производные аминотетралина в качестве антагонистов мускаринового рецептора
US20060241144A1 (en) Method for treating apathy syndrome